SCHEMBL1848

SCHEMBL1848

CC(=O)CCc1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
PLAAT3 P53816 2/20 0.54
PLAAT5 Q96KN8 2/20 0.54
PLAAT2 Q9NWW9 2/20 0.54
PLAAT4 Q9UL19 2/20 0.54
TAAR1 Q96RJ0 3/20 0.53
KMT2A Q03164 2/20 0.53
FFAR1 O14842 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
AOC3 Q16853 1/20 0.50
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3891167 0.89 PLAAT3 (0.57) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL18768957 0.86 ALDH1A1 (0.72) ALDH1A1FFAR1SMN1; SMN2KDM4EMAPT
SCHEMBL7332799 0.85 TAAR1 (0.57) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL6097422 0.85 TAAR1 (0.57) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL9626404 0.84 FFAR1 (0.56) ALDH1A1KMT2AFFAR1FFAR4SMN1; SMN2
SCHEMBL80581 0.83 ALDH1A1 (0.67) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
Benzylacetone SCHEMBL27421034 0.83 ALDH1A1 (0.81) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL3252805 0.83 PLAAT3 (0.55) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL9626424 0.82 MAOB (0.69) FFAR1FFAR4MAOAMAOB
SCHEMBL2473717 0.81 HTR3E (0.59) ALDH1A1PLAAT3PLAAT5PLAAT2PLAAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122038326-A Perakine reductase mutant and application thereof in double bond reduction 浙江大学 2026-05-15 CN disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
CN-111479806-B D-amino acid oxidase inhibitors and therapeutic uses thereof 心悦生医股份有限公司 2024-01-30 CN disclosed
US-11753400-B2 D-amino acid oxidase inhibitors and therapeutic uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-09-12 US disclosed
US-11753400-B2 D-amino acid oxidase inhibitors and therapeutic uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-09-12 US disclosed
US-11753400-B2 D-amino acid oxidase inhibitors and therapeutic uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-09-12 US disclosed
US-20200331894-A1 D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2020-10-22 US disclosed
US-20200331894-A1 D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2020-10-22 US disclosed
EP-3697763-A1 D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2020-08-26 EP disclosed
CN-111479806-A D-amino acid oxidase inhibitors and therapeutic uses thereof 心悦生医股份有限公司 2020-07-31 CN disclosed
US-20110082181-A1 Compounds as Lysophosphatidic Acid Receptor Antagonists Amira Phamaceuticals, Inc. (US) 2011-04-07 US disclosed
WO-2011041694-A2 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 WO disclosed
US-20110071289-A1 AMINOPYRAZOLE AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-03-24 US disclosed
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2010-11-11 US disclosed
EP-1889907-B1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME KANEKA CORP (JP) 2009-09-02 EP disclosed
EP-1889907-A1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2008-02-20 EP disclosed
US-20070054939-A1 Thiazolypiperidine derivatives as mtp inhibitors MERCK PATNET GMBH (DE) 2007-03-08 US disclosed
US-6369110-B1 PROPHYLACTIC AGENT FOR DISEASES CAUSED BY THE ACCELERATION OF THE SODIUM/PROTON EXCHANGE TRANSPORT SYSTEM SUMITOMO PHARMACEUTICALS COMPANY (JP) 2002-04-09 US disclosed
EP-1083166-A1 NOVEL SUBSTITUTED GUANIDINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-14 EP disclosed
US-4160036-A ADRENERGIC STIMULANTS ALLEN & HANBURYS LIMITED (GB) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331894-A1 D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF DAO, DDO, DDC ALDH1A1 243/4885PLAAT3 2312/4885PLAAT5 3117/4885
US-11753400-B2 D-amino acid oxidase inhibitors and therapeutic uses thereof DAO, DDO, DDC ALDH1A1 243/4885PLAAT3 2312/4885PLAAT5 3117/4885
US-20110082181-A1 Compounds as Lysophosphatidic Acid Receptor Antagonists LPAR1, LPAR2, LPAR4 ALDH1A1 3726/4885PLAAT3 80/4885PLAAT5 84/4885
US-20070054939-A1 Thiazolypiperidine derivatives as mtp inhibitors MTTP, CETP, APOB ALDH1A1 955/4885PLAAT3 1212/4885PLAAT5 972/4885
US-20110071289-A1 AMINOPYRAZOLE AMIDE DERIVATIVE ARGLU1, ARG1, CNKSR1 ALDH1A1 280/4885PLAAT3 2486/4885PLAAT5 3301/4885
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them BCAT1, AGXT, ALDH7A1 ALDH1A1 144/4885PLAAT3 405/4885PLAAT5 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.